Takayama Kanako, Nakamura Tatsuya, Takada Akinori, Kato Takahiro, Sakuma Hideo, Mitsudo Kenji, Fuwa Nobukazu, Murakami Masao
Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Fukushima 963-8052, Japan.
Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
Mol Clin Oncol. 2020 Oct;13(4):34. doi: 10.3892/mco.2020.2104. Epub 2020 Jul 30.
Ameloblastic carcinoma (AC) is a very rare malignant odontogenic tumor. Although surgical resection is generally performed, treatment approaches have not been established for recurrent cases. Chemotherapy and radiotherapy are positioned as adjunctive therapies, and few studies investigated definitive non-operative therapy. We present the case of a 71-year-old male with recurrent secondary-type AC arising from the right maxilla, who was treated with proton beam therapy (PBT; 71.4 Gy relative biological effectiveness in 32 fractions) combined with continuous intra-arterial infusion of cisplatin (40 mg/m) and docetaxel (8 mg/m). The patient experienced acute grade 3 mucositis, dermatitis and neutropenia, which were resolved within 3 months of treatment. Late adverse events were grade 1 skin atrophy, and grade 2 right optic nerve disorder and retinopathy. After ~8 years of treatment, the patient died from another cause but did not experience any relapse or metastasis during the follow-up period of 94 months. To the best of our knowledge, this is the first report of recurrent AC treated with PBT and intra-arterial infusion chemotherapy without any severe late adverse events. This combination therapy approach may be considered as an effective therapeutic option for inoperable AC.
成釉细胞癌(AC)是一种非常罕见的恶性牙源性肿瘤。尽管通常采用手术切除,但复发病例的治疗方法尚未确立。化疗和放疗被定位为辅助治疗,很少有研究探讨确定性非手术治疗。我们报告一例71岁男性患者,其右上颌骨出现复发性继发性AC,接受了质子束治疗(PBT;32次分割,相对生物效应为71.4 Gy),并联合持续动脉内输注顺铂(40 mg/m)和多西他赛(8 mg/m)。患者经历了3级急性黏膜炎、皮炎和中性粒细胞减少,在治疗3个月内得到缓解。晚期不良事件为1级皮肤萎缩、2级右侧视神经病变和视网膜病变。治疗约8年后,患者因其他原因死亡,但在94个月的随访期内未出现任何复发或转移。据我们所知,这是首例采用PBT和动脉内灌注化疗治疗复发性AC且无任何严重晚期不良事件的报告。这种联合治疗方法可被视为不可切除AC的一种有效治疗选择。